Please assess the completion status of the following clinical trial:

Trial Title: Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* over 18 years of age~* acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia~* onset of symptoms less than 6 hours~* measurable neurologic deficit (National Institutes of Health \[NIH\] Stroke Scale \>/= 1)~Exclusion Criteria:~* allergy to tetracycline antibiotics~* women of child-bearing potential~* known hepatic and/or renal insufficiency~* Thrombocytopenia~* history of intolerance to minocycline~* dizziness at the time of stroke or in the past month (by self-report)~* aphasia likely to interfere with patients ability to report adverse effects~* previous functional disability~* stuporous or comatose~* presence of another serious illness likely to confound the study~* unlikely to be available for 90 day follow-up~* severe stroke (National Institutes of Health \[NIH\] Stroke Scale \>22)~* undergoing an interventional neuro-radiological intervention in first 12 hour

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).